Vol. 6, Issue 1, Part A (2024)

In human chronic myeloid leukaemia, the tyrosine-kinase oncogene BCR/ABL1 is one of the key factors that determine most of its characteristics. Myeloproliferative diseases such as chronic myeloid leukaemia (CML) account for 15% of all new cases of leukemia, affecting 1–2 new cases per 100,000 every year. According to recent studies, the CRISPR/Cas9 system may be a definitive treatment option for chronic myeloid leukaemia. Scientists use genome editing technologies to add, remove, or alter genetic material at specific locations in the genome of an organism. Genome editing also goes by the name of gene editing because it allows scientists to change an organism's DNA. Nowadays, worldwide various genome editing has been discovered. But, in biomedical research, CRISPR/Cas9 (clustered regularly interspaced palindromic repeats) has caused a major revolution ingenome editing. Using CRISPR/Cas9 libraries and technology applications; we can achieve our goal of curing acute myeloid leukaemia within decades. In this review, we will discuss chronic myeloid leukaemia (CML) disease and future advances in genome editing that might help treat it. The novel technology will also be described in terms of its difficulties and ethical controversies.